Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment
- Supplementary File 1:
ZIP-Document (ZIP, 684 KiB)
Díaz-Barriga, C.; Villanueva-Flores, F.; Quester, K.; Zárate-Romero, A.; Cadena-Nava, R.D.; Huerta-Saquero, A. Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment. Pharmaceutics 2021, 13, 604. https://doi.org/10.3390/pharmaceutics13050604
Díaz-Barriga C, Villanueva-Flores F, Quester K, Zárate-Romero A, Cadena-Nava RD, Huerta-Saquero A. Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment. Pharmaceutics. 2021; 13(5):604. https://doi.org/10.3390/pharmaceutics13050604
Chicago/Turabian StyleDíaz-Barriga, Cristina, Francisca Villanueva-Flores, Katrin Quester, Andrés Zárate-Romero, Ruben D. Cadena-Nava, and Alejandro Huerta-Saquero. 2021. "Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment" Pharmaceutics 13, no. 5: 604. https://doi.org/10.3390/pharmaceutics13050604


